"Adenosine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
| Descriptor ID |
D000249
|
| MeSH Number(s) |
D03.633.100.759.646.138.180 D13.695.667.138.180 D13.695.827.068.180
|
| Concept/Terms |
2'-Adenylic Acid- 2'-Adenylic Acid
- 2' Adenylic Acid
- Acid, 2'-Adenylic
- 2'-Adenosine Monophosphate
- 2' Adenosine Monophosphate
- Monophosphate, 2'-Adenosine
- Adenylic Acid
- 2'-AMP
|
Below are MeSH descriptors whose meaning is more general than "Adenosine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Adenosine Monophosphate".
This graph shows the total number of publications written about "Adenosine Monophosphate" by people in this website by year, and whether "Adenosine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 5 | 0 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 6 | 0 | 6 |
| 2017 | 7 | 0 | 7 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenosine Monophosphate" by people in Profiles.
-
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011069.
-
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2022 01; 15(1):e010390.
-
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 07; 12(7):e007342.
-
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
-
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
-
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. Int J Cardiol. 2019 Mar 01; 278:217-222.
-
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
-
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circ Cardiovasc Interv. 2018 04; 11(4):e005635.
-
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Int J Cardiol. 2018 Jan 01; 250:49-55.
-
Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. Circ Cardiovasc Interv. 2017 Aug; 10(8).